Clearmind Medicine Expands Alcohol Use Disorder Trial in Israel
Ticker: CMND · Form: 6-K · Filed: Jun 23, 2025 · CIK: 1892500
Sentiment: neutral
Topics: clinical-trial, expansion, healthcare
TL;DR
Clearmind adds Israeli site to AUD trial, speeding up patient enrollment.
AI Summary
Clearmind Medicine Inc. announced on June 23, 2025, that it has added a leading Israeli clinical site to its ongoing clinical trial for Alcohol Use Disorder. This expansion aims to accelerate patient recruitment and data collection for the trial.
Why It Matters
This expansion could expedite the development of Clearmind's potential treatment for Alcohol Use Disorder, bringing it closer to market.
Risk Assessment
Risk Level: medium — The company is in clinical trials, which are inherently risky and may not result in a successful treatment.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- June 23, 2025 (date) — Announcement date
- Alcohol Use Disorder (medical_condition) — Condition being treated
FAQ
What is the specific name of the leading Israeli clinical site added to the trial?
The filing does not specify the name of the clinical site, only that it is a 'leading Israeli clinical site'.
What is the primary goal of adding this new clinical site?
The primary goal is to accelerate patient recruitment and data collection for the ongoing clinical trial for Alcohol Use Disorder.
What is the file number for Clearmind Medicine Inc.'s registration statement on Form F-3?
The file number for the registration statement on Form F-3 is 333-275991.
What is Clearmind Medicine Inc.'s fiscal year end?
Clearmind Medicine Inc.'s fiscal year end is October 31 (1031).
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 23, 2025 regarding Clearmind Medicine Inc. (CMND).